CGEN
Compugen Ltd.
CGEN trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over CGEN overall, supported by lower modeled downside and stronger valuation.
CGEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CGEN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.5x | $2.09 | -1.3% |
| Current | 5.7x | $2.12 | — |
| Fair | 6.5x | $2.48 | +17% |
| Expensive | 8x | $3.04 | +43% |
Historical ranges are pointers, not guarantees.
CGEN has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CGEN's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.38 | +$0.59 |
| Q1 2026 | $0.37 | +$0.53 |
| Q4 2025 | $0.37 | +$0.53 |
| Q3 2025 | -$0.30 | -1600% |
| Q2 2025 | -$0.21 | -$0.11 |
| Q1 2025 | -$0.16 | +$0.03 |
| Q4 2024 | -$0.16 | +$0.06 |
| Q3 2024 | $0.02 | +$0.39 |
CGEN has returned to profit: it earned $0.38 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CGEN on earnings, with more consistent year-over-year improvement.
CGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.6M | +107% |
| Q1 2026 | $2.2M | -4.7% |
| Q4 2025 | $67.3M | +4477% |
| Q3 2025 | $1.9M | -89% |
| Q2 2025 | $1.3M | -81% |
| Q1 2025 | $2.3M | -11% |
| Q4 2024 | $1.5M | -96% |
| Q4 2023 | $33.5M | +346% |
CGEN's revenue is growing: $3M last quarter, up 107% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -340% | +331 points |
| Q1 2026 | -414% | -47 points |
| Q4 2025 | 83% | +592 points |
| Q3 2025 | -417% | -444 points |
| Q2 2025 | -671% | -620 points |
| Q1 2025 | -368% | -36 points |
| Q4 2024 | -509% | -563 points |
| Q3 2024 | 26% | N/A |
CGEN's operating margin was −340% last quarter, up 331 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CGEN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CGEN on profitability, with a higher operating margin.
CGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | $0 |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
CGEN's free cash flow was $0 over the past year, against $0 the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CGEN on cash flow, with more consistent year-over-year improvement.
CGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +84.5K shares |
| 1 year | +1.2% | +1.1M shares |
| 3 years | +8.6% | +7.5M shares |
| 5 years | +13% | +10.8M shares |
| Available history | +45% | +29.2M shares |
CGEN has 95M diluted shares, up 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
CGEN hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -2.5x | Net Cash |
| Q3 2024 | -0.3x | Net Cash |
CGEN has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.8 | Neutral |
| Stochastic | 14.3 | Oversold |
CGEN's weekly RSI is 46 (neutral) and its Stochastic is 14 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CGEN PE vs Healthcare Sector
| Metric | CGEN | Sector median | Relative |
|---|---|---|---|
| PE | 5.7x | 26x | 78% below |
| PE % | 21 | 29 | 8 pts below |
CGEN has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.10 | 1% above |
| 20 week MA | $2.30 | 7.8% below |
| 50 week MA | $2.20 | 3.6% below |
| 100 week MA | $1.92 | 10% above |
| 200 week MA | $1.69 | 25% above |
CGEN's trend is mixed: it's above three of its five weekly moving averages, and 25% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CGEN on trend strength, trading above more of its moving averages.
CGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.16 | $13.1 | +113% |
| 2021 | $13.1 | $4.56 | -65% |
| 2022 | $4.56 | $0.76 | -83% |
| 2023 | $0.76 | $1.98 | +161% |
| 2024 | $1.98 | $1.57 | -21% |
| 2025 | $1.57 | $1.54 | -1.9% |
| 2026 YTD | $1.54 | $2.12 | +38% |
CGEN has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.